TCI Wealth Advisors’s Tourmaline Bio TRML Stock Holding History

TCI Wealth Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6	Closed	-$1K	–	2522
2021 Q3	$1K	Buy	+6	New	+$821	﹤0.01%	2314

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

TCI Wealth Advisors's TRML Position: Q4 2021 in Review

TCI Wealth Advisors sold out of Tourmaline Bio (TRML) in Q4 2021, closing a stake of 6 shares — an estimated $1K sold.

TCI Wealth Advisors first reported a position in TRML in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q4 2021.

TCI Wealth Advisors reported no remaining Tourmaline Bio position as of Q4 2021 after selling out during the quarter.
TCI Wealth Advisors sold 6 Tourmaline Bio shares in Q4 2021, an estimated $1K.
TCI Wealth Advisors first reported a position in Tourmaline Bio in Q3 2021 and held it in 1 quarter.
TCI Wealth Advisors's Tourmaline Bio position peaked at $1K in Q3 2021.
51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.